2022
PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER
Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER. Journal Of Urology 2022, 207: e44. DOI: 10.1097/ju.0000000000002518.07.Peer-Reviewed Original Research
2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsTranscription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.Peer-Reviewed Original ResearchCastration-resistant prostate cancerTranscription factor 4Prostate cancerTumor cellsAntiandrogen therapyNeuroendocrine differentiationFactor 4Group of patientsTranscription factor 4 expressionMessenger ribonucleic acid expressionFactor 4 expressionRibonucleic acid expressionChemotherapy treatmentPatientsDrug resistanceTherapyCancerChemotherapyCellsExpressionPhysiciansQuantifying publication rates and time to publication for urologic oncology podium presentations.
Mikhail M, Chua K, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. Journal Of Clinical Oncology 2021, 39: 357-357. DOI: 10.1200/jco.2021.39.6_suppl.357.Peer-Reviewed Original ResearchPodium presentationsAmerican Urological Association annual meetingsFull-length manuscriptsPeer-reviewed journalsMedian timeBladder cancerProstate cancerUrologic oncologyMedian journal impact factorPublication rateAnnual MeetingPresentationCancerPresentation abstractsAUA meetingMatching publicationsMeeting attendanceManuscript publicationConclusionAUA Annual MeetingJournal impact factorUnpublished researchAssociation Annual Meeting
2020
RNA-seq profile of African American men with a clinically localized prostate cancer
Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.Peer-Reviewed Original ResearchProstate cancer tissuesProstate cancerAfrican American menAA menCA menCancer tissuesPotential genetic risk factorSphingosine-1-phosphate signalingAmerican menExpression levelsGenetic risk factorsIngenuity Pathway AnalysisPathway analysisRNA sequencingPoor prognosisBiochemical recurrenceRadical prostatectomyRisk factorsLow expressionCancerMenCaucasiansSignificant differencesPatientsHigh rate
2019
Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor.
Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. PMID: 31139700, PMCID: PMC6526358.Peer-Reviewed Original ResearchImmune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancerMP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER
Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555316.15591.47.Peer-Reviewed Original ResearchReply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.Peer-Reviewed Original Research
2018
Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.Peer-Reviewed Original ResearchConceptsBladder cancerUrinary cell-free DNACell-free DNAScreening groupHematuria patientsValidation cohortPredictive valueUrine-based markersNegative predictive valuePositive predictive valueGood diagnostic performanceStudy cohortBC patientsUrological cancersNoninvasive biomarkersPatientsScore indexDiagnostic valueHematuriaExpression level ratioLiquid biopsyCohortDiagnostic performanceCancerDS-indexRole of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.Peer-Reviewed Original ResearchRenal cell carcinomaGenitourinary malignanciesAndrogen receptorBladder cancerRole of ARAdvanced disease stateProstate cancer developmentNovel therapeutic strategiesCell carcinomaTherapeutic armamentariumTherapeutic strategiesMortality rateCancer developmentMalignancyAndrogensDisease statesCancerCarcinomaProstateArmamentariumMolecular biologyDiseaseProgressionRoleReceptors
2017
MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Journal Of Urology 2017, 197: e765. DOI: 10.1016/j.juro.2017.02.1779.Peer-Reviewed Original Research
2016
Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 74. PMID: 27583246, PMCID: PMC4999522, DOI: 10.3389/fcell.2016.00074.Peer-Reviewed Original ResearchPD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER
Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER. Journal Of Urology 2016, 195: e59. DOI: 10.1016/j.juro.2016.02.2096.Peer-Reviewed Original Research
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapyMP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA
Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA. Journal Of Urology 2014, 191: e821. DOI: 10.1016/j.juro.2014.02.2235.Peer-Reviewed Original ResearchPD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER
Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER. Journal Of Urology 2014, 191: e896-e897. DOI: 10.1016/j.juro.2014.02.2428.Peer-Reviewed Original ResearchMP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES
Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES. Journal Of Urology 2014, 191: e927. DOI: 10.1016/j.juro.2014.02.2500.Peer-Reviewed Original ResearchDiagnosis of bladder cancer and prediction of survival by urinary metabolomics
Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.Peer-Reviewed Original ResearchConceptsBladder cancerControl groupCancer groupCancer-specific survival timeMuscle-invasive bladder cancerInvasive bladder cancerMetabolomic profilesPrediction of survivalHigh-performance liquid chromatography-quadrupole timeLiquid chromatography-quadrupole timeUrinary metabolomicsCommon cancerControl subjectsUrinary cytologyBC diagnosisDiagnostic modalitiesSurvival timeCurrent modalitiesUrine metabolitesMetabolomics-based approachPatientsCancerDifferential metabolitesClinical applicabilityCarnitine transferase
2013
Active surveillance in men with low-risk prostate cancer: current and future challenges.
Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. PMID: 25374902, PMCID: PMC4219278.Peer-Reviewed Original ResearchLow-risk prostate cancerActive surveillanceProstate cancerSurvival rateCancer-specific survival ratesProstate-specific antigen (PSA) screeningActive surveillance protocolsCost of overtreatmentActive surveillance programPSA kineticsAntigen screeningSurveillance protocolInstitutional protocolEligibility criteriaMortality rateNew biomarkersCancerSurveillance programLong-term studiesTreatment triggersInterventionMenGenetic testsSurveillanceContemporary review